Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2009

Radiant Strikes Deal with Spectrum to Provide CRO Services Across India

Radiant Strikes Deal with Spectrum to Provide CRO Services Across India

Radiant Research inks deal to expand in India

  • Radiant Research will forge a partnership with Spectrum Clinical Research to provide CRO and site services in India. Radiant will be able to monitor and manage studies in India along with offering seven sites in the Spectrum network.

    The services of both organizations will be available through a single contract and budget. The goal is to provide the services of an organization well versed in local culture and able to recruit quickly in India without sacrificing U.S.-level standards. Radiant and Spectrum overlap in therapeutic expertise and recruitment approach, easing coordination of research support.

    "This partnership will allow our sponsors to place a global trial through Radiant and know that the same quality and expertise they have come to expect from our organization will be realized at our partner organization in India," says Julie McHugh, vp of Radiant.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »